Iterum Therapeutics Received Notice of Delisting

Iterum Therapeutics has received a notice from Nasdaq regarding the delisting of its ordinary shares due to the withdrawal of its appeal against a previous delisting decision. This decision was made because the company failed to maintain the required minimum bid price of $1.00. Trading will be suspended on April 1, 2026, and a Form 25-NSE will be filed to officially remove the shares from Nasdaq.

On March 30, 2026, Nasdaq notified the company that its ordinary shares will be delisted after it withdrew its appeal of a prior delisting determination stemming from failure to maintain the $1.00 minimum bid price. Trading will be suspended at the open on April 1, 2026, and a Form 25-NSE will be filed to remove the shares from Nasdaq.

Original SEC Filing: Iterum Therapeutics plc [ ITRM ] - 8-K - Mar. 31, 2026

Disclaimer

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.